Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Kadcyla | Trastuzumab emtansine | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kadcyla | Trastuzumab Emtansine | Early Breast Cancer (EBC) | Reimburse | Complete | ||
Kalydeco | Ivacaftor | Cystic fibrosis, R117H CFTR gating mutation | List with criteria/condition | Complete | ||
Kalydeco | Ivacaftor | Cystic Fibrosis, CFTR gating mutations | List with criteria/condition | Complete | ||
Kalydeco | Ivacaftor | Cystic fibrosis, G551D mutation | List with criteria/condition | Complete | ||
Kanuma | sebelipase alfa | Lysosomal acid lipase deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | ||
Kerendia | finerenone | Chronic kidney disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Kesimpta | ofatumumab | Multiple Sclerosis, relapsing | Reimburse with clinical criteria and/or conditions | Complete | ||
Kevzara | sarilumab | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete |